Cardiovascular Outcomes of New Medications for Type 2 Diabetes.

Abstract

Cardiovascular (CV) disease remains the leading cause of death in people with diabetes, highlighting the importance of using treatment options that do not increase CV risk or possibly decrease CV outcomes. Since 2008, the Food and Drug Administration has required demonstration of CV safety for all new medications developed for the glycemic management of diabetes. Seven trials have been published that have established CV safety for three DPP-4 inhibitors (alogliptin, saxagliptin, and sitagliptin), three GLP-1 receptor agonists (liraglutide, lixisenatide, and semaglutide), and one sodium-glucose cotransporter-2 inhibitor (empagliflozin). Three of those studies also established superiority with liraglutide, empagliflozin, and semaglutide at reducing the composite primary endpoint of major CV events (CV death, nonfatal myocardial infarction, and nonfatal stroke). In addition, one trial found an increase in heart failure hospitalizations with saxagliptin. The findings of these trials must be compared and contrasted cautiously given the differences in patient populations and trial designs, but together they provide important information that can be used to shape our treatment guideline recommendations and patient-specific treatment decisions.

• Authors: Jennifer M Trujillo, Sara A Wettergreen, Wesley A Nuffer, Samuel L Ellis, Michael T McDermott
• Journal: Diabetes technology & therapeutics (Diabetes Technol Ther) Vol. 18 Issue 12 Pg. 749-758 (12 2016) ISSN: 1557-8593 [Electronic] United States
• PMID: 27835045 (Publication Type: Journal Article, Review)

Chemical References

• Hypoglycemic Agents

Topics

• Cardiovascular Diseases (chemically induced, prevention & control)
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Humans
• Hypoglycemic Agents (adverse effects)